Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Public ClinicalTrials.gov record NCT06120140. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (\>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management and with modified enhanced dermatologic management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. The study also includes Expansion cohorts (in 2 different schedules) to evaluate enhanced dermatologic management and early intervention for DAEIs or paronychia, in participants receiving subcutaneous amivantamab and lazertinib. A substudy will enroll participants from Arms A and B who experience specific new-onset or persistent DAEIs (Grade \>=2) during treatment with intravenous (IV) amivantamab and lazertinib. This substudy aims to assess the reactive use of dermatologic treatment strategies in these participants.
Study identification
- NCT ID
- NCT06120140
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 305 participants
Conditions and interventions
Conditions
Interventions
- Amivantamab IV Drug
- Amivantamab SC Drug
- Lazertinib Drug
- Doxycycline Drug
- Minocycline Drug
- Clindamycin Drug
- Chlorhexidine Drug
- Noncomedogenic skin moisturizer Other
- Ruxolitinib Other
- Tacrolimus Other
- Zinc gluconate Drug
- Propranolol Drug
- Timolol Drug
- Clobetasol Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 16, 2024 (Actual)
- Primary completion
- May 31, 2027 (Estimated)
- Completion
- Jun 30, 2030 (Estimated)
- Last update posted
- Sep 25, 2026
2024 – 2030
United States locations
- U.S. sites
- 28
- U.S. states
- 13
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer and Research Center | Chandler | Arizona | 85224 | — |
| City of Hope | Duarte | California | 91010 | — |
| Providence Fullerton | Fullerton | California | 92835 | — |
| Los Angeles Cancer Network | Glendale | California | 91204 | — |
| City of Hope Seacliff | Huntington Beach | California | 92648 | — |
| City of Hope Orange County Lennar Foundation Cancer Center | Irvine | California | 92618 | — |
| City of Hope Long Beach Elm | Long Beach | California | 90813 | — |
| Cancer and Blood Specialty Clinic | Los Alamitos | California | 90720 | — |
| Keck Hospital of USC | Los Angeles | California | 90033 | — |
| USC Norris Oncology Hematology Newport Beach | Newport Beach | California | 92663 | — |
| Kaiser Permanente Oakland Medical Center | Oakland | California | 94611 | — |
| Kaiser Permanente Roseville Medical Center | Roseville | California | 95661 | — |
| Kaiser Permanente San Francisco Medical Center | San Francisco | California | 94115 | — |
| Kaiser Permanente Santa Clara Medical Center | Santa Clara | California | 95051 | — |
| City of Hope South Pasadena | South Pasadena | California | 91030 | — |
| Kaiser Permanente Northern California | Vallejo | California | 94589 | — |
| Kaiser Permanente Walnut Creek Medical Center | Walnut Creek | California | 94596 | — |
| University Cancer & Blood Center | Athens | Georgia | 30607 | — |
| Hope and Healing Care | Hinsdale | Illinois | 60521 | — |
| Oncology Hematology Associates | Springfield | Missouri | 65807 | — |
| Renown Health Medical Oncology | Reno | Nevada | 89502 | — |
| Hunterdon Hematology Oncology | Flemington | New Jersey | 08822 | — |
| Clinical Research Alliance Inc | Westbury | New York | 11590 | — |
| Regional Medical Oncology Center | Wilson | North Carolina | 27893 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Valley Medical Center | Renton | Washington | 98055 | — |
| Gundersen Health System | West Salem | Wisconsin | 54669 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06120140, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06120140 live on ClinicalTrials.gov.